Home › Funds › Defilade Capital Management, L.P. › EVMN

Defilade Capital Management, L.P. position in EVMN

EVOMMUNE INC · Health Care

Defilade Capital Management, L.P. reported holding 793,145 shares of EVMN (EVOMMUNE INC) in its Q2 2026 13F filing — a position valued at US$10.5M, representing 1.41% of its reported portfolio and ranking #30 among its reported holdings. Defilade Capital Management, L.P. has disclosed EVMN holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)793.14K sh
Reported value held$10.54M
Portfolio Weight1.41%
First reportedQ4 2025
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Defilade Capital Management, L.P.'s EVMN position evolved

Defilade Capital Management, L.P. first disclosed a stake in EVMN in Q4 2025 at 215,418 shares (US$3.7M). The position peaked in Q1 2026 at 678,589 shares, worth US$15.6M. Across 3 filings, Defilade Capital Management, L.P. increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 793,145 shares valued at US$10.5M — an increase of 114,556 shares quarter over quarter.. Notable position changes include a 215% increase in Q1 2026 (shares fell 42% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 215.42K $3.69M New
Q1 2026 678.59K $15.60M Add
Q2 2026 793.14K $10.54M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About EVMN and 13F data

EVMN (EVOMMUNE INC) is a Health Care company. 116 other funds we track also report a position in EVMN — the largest reported positions include EQT Fund Management S.a r.l. (US$70.3M), RA CAPITAL MANAGEMENT, L.P. (US$46.4M), SymBiosis Capital Partners, LLC (US$29.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding EVMN

All EVMN fund holders →

FAQ

How long has Defilade Capital Management, L.P. held EVMN?

Defilade Capital Management, L.P. has disclosed EVMN holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

What is Defilade Capital Management, L.P.'s current position in EVMN?

As of Q2 2026, Defilade Capital Management, L.P. holds 793.14K shares of EVMN (EVOMMUNE INC), valued at $10.54M, representing 1.41% of its reported portfolio and ranking #30.

Has Defilade Capital Management, L.P. been buying or selling EVMN?

In the latest 13F filing (Q2 2026), Defilade Capital Management, L.P. increased its position in EVMN. The position peaked in Q1 2026 at 678.59K shares.

Which other funds hold EVMN?

Other major institutional holders of EVMN include EQT Fund Management S.a r.l., RA CAPITAL MANAGEMENT, L.P., SymBiosis Capital Partners, LLC, among 116 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.